Industry news that matters to you.  Learn more

Archives for February 2017

New Biomarker Allows Better Prediction of Survival for Patients with Colorectal Metastases

Liver metastases are formed from cancer cells that have originated in other organs and migrated to the liver via the bloodstream. Colorectal cancer (cancer of the colon/rectum) can be successfully treated by surgical resection of the metastases in combination with chemotherapy. In collaboration with the University of Southern California (USA), a MedUni Vienna research team has now identified a new biomarker that allows better prediction of survival following surgical removal of the metastases, as well as a change in the clinical significance of the biomarker following chemotherapy.

Tau Shalt Not Return to Play

This January, former New York Jets defensive end Mark Gastineau told a radio show host that he had been diagnosed with dementia, Alzheimer’s Disease, and Parkinson’s Disease. The Jets all-time leader in sacks said he believes his ailments were caused by playing football. The revelations came just a few weeks before the Super Bowl, the most widely viewed event in sports.

Induced Pluripotent Stem Cells: Proteomics Test

Stem cells have the ability to continue dividing and renewing for long periods of up to a year or more and transform from their unspecialised structures into specialised cell types such as heart muscle cells or nerve cells. It was news of these properties that created such as buzz in recent years, with the possibility of generating new tissue to replace damaged or unhealthy tissue in the human body.

Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits

Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology and personalized molecular diagnostics®, today announces the expansion of its long-term collaboration agreement with Thermo Fisher Scientific to include development and commercialization of in vitro diagnostic (IVD) assays for the Applied Biosystems® 3500 Dx Series Genetic Analyzers. The company’s previously announced agreement focuses on the development of IVD oncology tests for the Ion PGM™ Dx System.